Trending...
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains. As opposed to gray matter, which is composed of the cell bodies of neurons, white matter is made up of cells that produce myelin, a fatty substance that coats neurons, offering protection and helping them transmit signals efficiently. A reduction in white matter is associated with motor and cognitive impairment.
Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)—the lifesaving drugs that many with HIV use daily—can reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production. When the researchers applied a compound blocking to this process, the cells were once again able to mature. The work appears in the journal Glia.
More on The PennZone
"Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto, professor at Penn Dental Medicine and the study's co-senior author. "By understanding those mechanisms, we can take the next step to protect people with HIV from these impacts."
Jordan-Sciutto and Judith Grinspan, CHOP research scientist and Professor of Neurology at Penn Medicine, have been collaborating to elucidate how ART and HIV affect the brain. Their previous work on antiretrovirals had shown that commonly used drugs disrupted the function of oligodendrocytes, reducing myelin formation.
More on The PennZone
In the current study, they aimed to isolate the effect of HIV on this process by looking at human macrophages, one of the major cell types that HIV infects.
Ultimately, the researchers want to discern the effects of the virus from the drugs used to treat it in order to better evaluate the risks of each.
"When we put people on ART, it's important to understand the implications," says Jordan-Sciutto. "Antiretrovirals may prevent the establishment of a viral reservoir in the central nervous system, which would be wonderful, but we also know some drugs have unintended consequences, which may include altering white matter." Read more on the study >>
Contact: Beth Adams, [email protected]
SOURCE Penn Dental Medicine
Related Links
http://www.dental.upenn.edu
Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)—the lifesaving drugs that many with HIV use daily—can reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production. When the researchers applied a compound blocking to this process, the cells were once again able to mature. The work appears in the journal Glia.
More on The PennZone
- Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
- Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
- Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
- Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
- Can Government Operate Better Through Innovation?
"Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto, professor at Penn Dental Medicine and the study's co-senior author. "By understanding those mechanisms, we can take the next step to protect people with HIV from these impacts."
Jordan-Sciutto and Judith Grinspan, CHOP research scientist and Professor of Neurology at Penn Medicine, have been collaborating to elucidate how ART and HIV affect the brain. Their previous work on antiretrovirals had shown that commonly used drugs disrupted the function of oligodendrocytes, reducing myelin formation.
More on The PennZone
- Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
- Her Song Lives On: Remembering Mrs. Darlene Davis Porter
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Pittsburgh Creators Launch Clever New Children's Book, "The Sock Sleuth!"
- Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
In the current study, they aimed to isolate the effect of HIV on this process by looking at human macrophages, one of the major cell types that HIV infects.
Ultimately, the researchers want to discern the effects of the virus from the drugs used to treat it in order to better evaluate the risks of each.
"When we put people on ART, it's important to understand the implications," says Jordan-Sciutto. "Antiretrovirals may prevent the establishment of a viral reservoir in the central nervous system, which would be wonderful, but we also know some drugs have unintended consequences, which may include altering white matter." Read more on the study >>
Contact: Beth Adams, [email protected]
SOURCE Penn Dental Medicine
Related Links
http://www.dental.upenn.edu
0 Comments
Latest on The PennZone
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- The Social Capital Revolution Comes to Phoenix!
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
- FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
- Bettingbladet releases H1 2026 report on the Swedish online gambling market
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- SMACK Fight Week Takes Over Philadelphia
- Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
- Spearmint Publishes Full Design of Its Mining Pool Before Building It, Including Legal Drafts
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
- Brewtay Coffee Introduces Specialty Instant Line Designed for High-Velocity Commuters and Travelers
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Ten Ten Ten Awards Provisional Certification to Cara AI for Home-Based Health Assessments
- IDI Consulting Partners with the American Heart Association to Advance Heart Health Awareness
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Diversity Committee
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)